Exicure, Purdue deal

Exicure granted Purdue exclusive options to license treatments for psoriasis and other diseases amenable to gene regulation. The deal includes an option for worldwide development and commercialization rights to AST-005, plus three additional targets to be selected later. AST-005 is a topical spherical nucleic acid-based therapeutic targeting tumor necrosis factor (TNF) and has completed Phase I testing to treat psoriasis...